The DOI matches its Crossref record; 675 of the 676 references it cites were found in a registry or an index.
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Open accessAbstract
Epigenetic alternations concern heritable yet reversible changes in histone or DNA modifications that regulate gene activity beyond the underlying sequence. Epigenetic dysregulation is often linked to human disease, notably cancer. With the development of various drugs targeting epigenetic regulators, epigenetic-targeted therapy has been applied in the treatment of hematological malignancies and has exhibited viable therapeutic potential for solid tumors in preclinical and clinical trials. In this review, we summarize the aberrant functions of enzymes in DNA methylation, histone acetylation and histone methylation during tumor progression and highlight the development of inhibitors of or drugs targeted at epigenetic enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Simvastatin, a cholesterol-lowering drug, displays anti-tumor effects in GBM by inducing apoptosis and inhibiting cell migration and invasion30.”
From Multi-omics analysis identifies glioblastoma dependency on H3K9me3 methyltransferase activity (2025) · cites this paper as [30]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10 retracted
Expression of DNMT1 and DNMT3a Are Regulated by GLI1 in Human Pancreatic Cancer
He, S., Wang, F., Yang, L., Guo, C., Wan, R., Ke, A., Xu, L., Hu, G., Xu, X., Shen, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027684 · Cited by 88 · cited 1×
“cancer, the APC gene, encoding a regulator of cell junctions, is hypermethylated by DNMT overexpression.(29) During an analysis of colorectal disease methylation patterns, researchers found several genes that showed significant changes between precancerous diseases and cancers, including RUNX3, NEUROG1, CACNA1G, SFRP2…”
BackgroundRetractedcircZMYM2 Competed Endogenously with miR-335-5p to Regulate JMJD2C in Pancreatic Cancer
An, Y., Cai, H., Zhang, Y., Liu, S., Duan, Y., Sun, D., Chen, X., & He, X. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495868 · Cited by 79
RetractedZhao, X., Zheng, F., Li, Y., Hao, J., Tang, Z., Tian, C., Yang, Q., Zhu, T., Diao, C., Zhang, C., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.10.018 · Cited by 72
RetractedLi, T., Zheng, Q., An, J., Wu, M., Li, H., Gui, X., Pu, H., & Lu, D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.208 · Cited by 57
RetractedHou, X., Gong, R., Zhan, J., Zhou, T., Ma, Y., Zhao, Y., Zhang, Y., Chen, G., Zhang, Z., Ma, S., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4559-3 · Cited by 36
RetractedCai, M., Chen, Q., Shen, J., Lv, C., & Cai, L. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13716 · Cited by 31
RetractedRETRACTED: Kaiso is expressed in lung cancer: Its expression and localization is affected by p120ctn
Dai, S., Wang, Y., Jiang, G., Zhang, P., Dong, X.-J., Wei, Q., Xu, H., Li, Q., Zhao, C., & Wang, E. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.013 · Cited by 29
RetractedRETRACTED ARTICLE: TET2 inhibits tumorigenesis of breast cancer cells by regulating caspase-4
Zhu, X., & Li, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-34462-z · Cited by 29
RetractedZhang, J., Liu, M., Liu, W., & Wang, W. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1593857 · Cited by 13
RetractedSun, S., Zhang, Y., Zheng, J., Duan, B., Cui, J., Chen, Y., Deng, W., Ye, B., Liu, L., Chen, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0931-0 · Cited by 11
Retracted
Research works printed but not linked: 2
- Feng, Q. & Zhang, Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15, 827–832 (2001).
- Chen, X. F. et al. SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep. 19, e45124 (2018).
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Self-citationMetabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
“…SAM cycle inhibitors and other inhibitors or activators of epigenetic modulation in cancer, please see the excellent reviews by Falkenberg et al., Eckschlager et al., Wong et al. and Cheng et al. (Falkenberg and Johnstone, 2014; Eckschlager et al., 2017; Wong et al., 2017; Cheng et al., 2019).”
BackgroundTumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Oxidative Stress: The Role of Antioxidant Phytochemicals in the Prevention and Treatment of Diseases
Muscolo, A., Mariateresa, O., Giulio, T., & Mariateresa, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063264 · Cited by 454
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
“Sodium butyrate and phenyl butyrate compounds, often in combination with other drugs, were tested in a number of phase I–III clinical trials for different types of tumor such as: leukemia, lung cancer, lymphoma, multiple myeloma, and prostate cancer [232].”
Background
Metadata
- Authors
- Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Wei, Xiawei
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2019-12-17
- Volume
- 4
- Issue
- 1
- Pages
- 62-62
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC6915746
- OpenAlex
- W2995898384
- Cited by
- 1,097
- References
- 676
- Citations by year
- 2026: 75 · 2025: 157 · 2024: 198 · 2023: 217 · 2022: 175 · 2021: 190 · 2020: 77
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (No. 81602950)
- National Key Research and Development Program of China
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- epigenetic regulators, DNA methylation, histone acetylation, histone methylation, epigenetic enzymes, enzyme inhibitors, hematologic malignancies, solid tumors, tumor progression, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. https://app.cochat.ai/papers/10.1038/s41392-019-0095-0
- The paper
- Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019). Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-019-0095-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.